SCHEMBL4960969

SCHEMBL4960969

N#Cc1c(NC(=O)C2CC2c2ccoc2)sc2c1CCNC2

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.42
HPGD P15428 5/20 0.42
LMNA P02545 3/20 0.42
POLB P06746 3/20 0.42
NPC1 O15118 5/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
RAB9A P51151 4/20 0.40
GAA P10253 2/20 0.40
KMT2A Q03164 3/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PKM P14618 1/20 0.39
MAPK10 P53779 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2894559 0.87 ALDH1A1 (0.47) ALDH1A1HPGDLMNAPOLBNPC1
SCHEMBL4961044 0.85 ALDH1A1 (0.48) ALDH1A1HPGDLMNAPOLBNPC1
SCHEMBL4964396 0.84 MAPK10 (0.46) ALDH1A1HPGDLMNAPOLBNPC1
SCHEMBL2894032 0.83 ALDH1A1 (0.44) ALDH1A1HPGDLMNAPOLBNPC1
SCHEMBL2887971 0.82 LMNA (0.48) ALDH1A1HPGDLMNAPOLBSMN1; SMN2
SCHEMBL4961190 0.82 SMN1; SMN2 (0.48) ALDH1A1HPGDLMNAPOLBNPC1
SCHEMBL4960071 0.82 TP53 (0.43) ALDH1A1HPGDLMNAPOLBNPC1
SCHEMBL4961200 0.82 ALDH1A1 (0.41) ALDH1A1HPGDLMNAPOLBNPC1
SCHEMBL4960995 0.81 MAPK10 (0.47) ALDH1A1HPGDLMNAPOLBNPC1
SCHEMBL4960036 0.80 ALDH1A1 (0.43) ALDH1A1HPGDLMNAPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896484-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER Nycomed GmbH (DE) 2008-03-12 EP disclosed
WO-2006125813-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER NYCOMED GMBH (DE) 2006-11-30 WO disclosed